Biofrontera Completes Phase 3 Trial for Ameluz PDT in Actinic Keratoses

Biofrontera Inc. has announced that the final patient has completed the active treatment phase of its Phase 3 clinical trial for Ameluz® PDT in actinic keratoses (AKs) on the extremities, neck, and trunk. All 172 enrolled patients have entered the 12-month follow-up phase, with study results expected to form the basis of a supplemental New Drug Application (sNDA) planned for submission in Q2 2026.